>
Erika Kirk shares update after private in-person meeting with Candace Owens
Candace Owens Reacts to Erika Kirk's Interviews and Comments about Questioning TPUSA
Bank of America just leaked their report to institutional clients.
IDEAL HUB TO KICK OFF THE GRAND PLAN: BIRTH OF "USAMERICAS"
This tiny dev board is packed with features for ambitious makers
Scientists Discover Gel to Regrow Tooth Enamel
Vitamin C and Dandelion Root Killing Cancer Cells -- as Former CDC Director Calls for COVID-19...
Galactic Brain: US firm plans space-based data centers, power grid to challenge China
A microbial cleanup for glyphosate just earned a patent. Here's why that matters
Japan Breaks Internet Speed Record with 5 Million Times Faster Data Transfer
Advanced Propulsion Resources Part 1 of 2
PulsarFusion a forward-thinking UK aerospace company, is pushing the boundaries of space travel...
Dinky little laser box throws big-screen entertainment from inches away
'World's first' sodium-ion flashlight shines bright even at -40 ºF

Known as "histotripsy," the method and machinery have already been tested successfully in animals and humans, and has just been approved for use by the FDA.
HistoSonics is a company founded in 2009 to create an ultrasound device that both screens for tumors and administers histotripsy. It was born from the efforts of scientists at the University of Michigan who co-founded the firm.
"Histotripsy is an exciting new technology that, although it is in early stages of clinical use, may provide a noninvasive treatment option for patients with liver cancer. Hopefully it can be combined with systemic therapies for a synergistic therapeutic effect," said Mishal Mendiratta-Lala, professor of radiology with Michigan Medicine.
Mendiratta-Lala was the principal investigator of an FDA human trial started in 2021 which confirmed that HistoSonic's device, called Edison, can destroy cancer tumors.